Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26

Article  PubMed  Google Scholar 

Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49–59.

Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C et al (2017) CUA guideline on adult overactive bladder. Can Urol Assoc J 11(5):E142–E173

Article  PubMed  PubMed Central  Google Scholar 

Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT et al (2024) The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol 212(1):11–20

Article  PubMed  Google Scholar 

Araklitis G, Robinson D, Cardozo L (2020) Cognitive effects of anticholinergic load in women with overactive bladder. Clin Interv Aging 15:1493–1503

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lozano-Ortega G, Johnston KM, Cheung A, Wagg A, Campbell NL, Dmochowski RR et al (2020) A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr 87:103885

Article  CAS  PubMed  Google Scholar 

Lua LL, Pathak P, Dandolu V (2017) Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn 36(8):2123–2131

Article  CAS  PubMed  Google Scholar 

Kennelly M, Wielage R, Shortino D, Thomas E, Mudd PN, Jr. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022;11.

Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS et al (2017) Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 120(4):562–575

Article  CAS  PubMed  Google Scholar 

Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee KS et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev 75(4):554–674

Article  CAS  PubMed  Google Scholar 

Wada N, Mizunaga M, Abe N, Miyauchi K, Kobayashi S, Ohtani M et al (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42(1):113

Article  CAS  PubMed  Google Scholar 

Ohlstein EH, von Keitz A, Michel MC (2012) A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62(5):834–840

Article  CAS  PubMed  Google Scholar 

Abe Y, Nakano Y, Kanazawa T, Furihata T, Endo T, Kobayashi M (2016) Investigation of drug-drug interactions between ritobegron, a selective β3 -adrenoceptor agonist, with probenecid in healthy men. Clin Pharmacol Drug Dev 5(3):201–207

Article  CAS  PubMed  Google Scholar 

Jian Z, Yuan C, Li H, Zhang W, Wang K (2020) Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. Int Urol Nephrol 52(12):2215–2221

Article  PubMed  Google Scholar 

He W, Zhang Y, Huang G, Tian Y, Sun Q, Liu X (2023) Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis. Low Urin Tract Symptoms 15(3):80–88

Article  CAS  PubMed  Google Scholar 

Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z et al (2019) Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn 38(1):22–30

Article  PubMed  Google Scholar 

Mukai S, Nomi M, Yamada S, Yanagiuchi A, Sengoku A (2021) The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: a retrospective comparative study in a rehabilitation hospital in Japan. Low Urin Tract Symptoms 13(4):448–455

Article  CAS  PubMed  Google Scholar 

Sato H, Otsuka S, Tsukada S (2023) Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial. Low Urin Tract Symptoms 15(4):129–138

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D et al (2016) Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 70(1):136–145

Article  CAS  PubMed  Google Scholar 

Hutton BSG, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784

Article  PubMed  Google Scholar 

Blaivas JG, Panagopoulos G, Weiss JP, Somaroo C. Validation of the overactive bladder symptom score. J Urol. 2007;178(2):543–7; discussion 7.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Welch VA. Cochrane handbook for systematic reviews of interventions: Cochrane handbook for systematic reviews of interventions; 2019.

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R et al (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 67(3):577–588

Article  CAS  PubMed  Google Scholar 

Anwar A, Gorka V, Chahal HS, Sharma S, Tandon S, Singhal N et al (2023) Comparison of efficacy and safety of a combination of tamsulosin and mirabegron versus tamsulosin alone in the management of overactive bladder in males with lower urinary tract symptoms - TAME-overactive bladder: an open-labeled randomized controlled trial. Int J Appl Basic Med Res 13(4):218–223

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kakizaki H, Lee KS, Katou D, Yamamoto O, Sumarsono B, Uno S et al (2021) Mirabegron add-on therapy to tamsulosin in men with overactive bladder: post hoc analyses of efficacy from the MATCH study. Adv Ther 38(1):739–757

Article  CAS  PubMed  Google Scholar 

Kumar S, Tiwari V, Chaurasia DK, Kumar S, Mishra S (2023) A comparative study of solifenacin, mirabegron, and their combination as bladder relaxants in the management of overactive bladder. Cureus 15(9):e45612

PubMed  PubMed Central  Google Scholar 

Mitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S et al (2019) Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol 75(2):274–282

Article  CAS  PubMed  Google Scholar 

Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr (2020) International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204(2):316–324

Article  PubMed  Google Scholar 

Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S (2024) Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol 212(2):256–266

Article  PubMed  Google Scholar 

Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O et al (2019) Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study). Int J Urol 26(3):342–352

Article  CAS  PubMed  Google Scholar 

Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T (2018) Vibegron, a novel potent and selective β(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 73(5):783–790

Article  CAS  PubMed  Google Scholar 

Farag F, Sakalis V, Arteaga S, Sihra N, Karavitakis M, Arlandis S et al (2023) What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel. Eur Urol 84(3):302–312

Article  CAS  PubMed  Google Scholar 

Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, F